DEA Finalizes Significant Increases in Psychedelic Production Quotas for 2026 to Support PTSD and Depression Research
核心洞察
The Drug Enforcement Administration (搜索) has finalized production quotas for 2026 that substantially increase legal manufacturing of psychedelics including psilocybin, psilocyn (搜索), and DMT for research into PTSD (搜索) and depression (搜索) treatments.
Psilocyn (搜索) quotas more than doubled from 36,000 grams in 2025 to 80,000 grams in 2026, while psilocybin increased from 30,000 to 50,000 grams following public feedback.
The quota increases reflect growing scientific interest in psychedelic therapeutics, with some compounds like 5-MeO-DMT seeing dramatic growth from just 35 grams in 2021 to 30,000 grams in 2026.
The Drug Enforcement Administration (搜索) has finalized production quotas for controlled substances in 2026, implementing substantial increases for several psychedelics to support research into their therapeutic potential for treating post-traumatic stress disorder (搜索) and depression (搜索).
In a notice published in the Federal Register on Monday, DEA increased its quotas for psilocybin, psilocyn (搜索) and DMT compared to what the agency proposed in its draft rule in November. The agency stated it was moving to boost the quotas for these psychedelic substances so researchers can study whether they could serve as "potential treatment of conditions such as post-traumatic stress disorder (搜索) (PTSD (搜索)) and depression (搜索)."
Dramatic Quota Increases Following Public Input
Based on public comments the agency received, DEA said the amounts were adjusted to be "at higher levels than were proposed," without expanding on the specific rationale for the individual quota increases.
The production goal for psilocybin rose from 30,000 grams last year to 40,000 grams in the initial rule for this year—and has now been raised to 50,000 grams in 2026's final rule. The psilocyn (搜索) quota increased from 36,000 grams in 2025 to 48,000 grams in the initial 2026 rule before being raised again to 80,000 grams in the final rule for 2026—more than doubling in the span of a year.
For DMT, DEA is proposing to increase the quota from 20,000 grams last year to 25,000 grams in 2026. In the agency's initial rule for this year, the quota for that psychedelic remained the same but has since been revised in the final rule following public feedback.
Sustained Growth in Lesser-Known Compounds
Other substances that saw increases from last year in 2026's initial rule have not been further adjusted in the new final rule. That is the case for methylone, an MDMA-like compound. In 2025, the agency set a goal of 5,200 grams, but in 2026 it wants 30,000 grams produced. The production goal for the substance was minuscule four years ago, when DEA proposed the manufacturing of just 40 grams.
DEA set a quota of 30,000 grams of 5-MeO-DMT to be produced in 2026—an increase from 11,000 grams last year. That represents a substantial boost from 2021's quota of just 35 grams, demonstrating the rapid expansion of research interest in this compound.
Regulatory Framework and Future Implications
"These proposed 2026 quotas reflect the quantities that DEA believes are necessary to meet the estimated medical, scientific, research, and industrial needs of the United States, lawful export requirements; and the establishment and maintenance of reserve stocks," DEA said in its proposed rule in November.
The agency said that, in setting the quotas, it took into account several factors, including "projected demand for such class as indicated by procurement quotas," information obtained by federal health agencies such as the Food and Drug Administration (搜索) and "other factors affecting medical, scientific, research, and industrial needs in the United States and lawful export requirements."
Over recent years, DEA has generally ramped up production goals for marijuana and certain psychedelics as interest in their therapeutic potential has grown within the public and scientific community. The proposed 2026 quotas for cannabis, THC, ibogaine, MDMA, LSD and mescaline were not adjusted since last year, however.
The Controlled Substances Act requires the attorney general to set annual production quotas for Schedule I and Schedule II drugs each year. Notably, marijuana would not be part of this annual research production list if the Justice Department follows through on an executive order signed by President Donald Trump directing the attorney general to move cannabis from Schedule I to Schedule III.